Reply

Authors

  • Nik Arsyad Nik Muhamad Affendi Division of Gastroenterology and Hepatology, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; Division of Gastroenterology and Hepatology, Faculty of Medicine, International Islamic University of Malaysia, Kuantan, Malaysia
  • Choon Jin Ooi Duke-NUS Medical School, Gleneagles Medical Centre, Singapore
  • Ida Normiha Hilmi Division of Gastroenterology and Hepatology, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

DOI:

https://doi.org/10.15403/jgld-5217

Keywords:

ustekinumab, ulcerative colitis, Crohn's disease, inflammatory bowel disease

Downloads

Published

2023-09-29

How to Cite

1.
Affendi NANM, Ooi CJ, Hilmi IN. Reply. JGLD [Internet]. 2023 Sep. 29 [cited 2025 Jun. 21];32(3):412-3. Available from: https://jgld.ro/jgld/index.php/jgld/article/view/5217

Issue

Vol. 32 No. 3: September 2023

Section

Letters